H.C. Wainwright Adjusts Price Target for AngioDynamics (NASDAQ: ANGO) Amid Q1 Fiscal 2027 Results

  • H.C. Wainwright maintained its Buy rating on AngioDynamics but lowered its price target to $18.
  • AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027.
  • Despite positive Q1 results and strong Med Tech sales, AngioDynamics' shares experienced a significant drop of over 21%.

H.C. Wainwright maintains its Buy rating on AngioDynamics (NASDAQ: ANGO) but lowers its price target from $19 to $18. The medical device stock trades at $10.68 when the update is posted. AngioDynamics makes medical devices, including its Auryon, AlphaVac and NanoKnife products.

The rating update follows AngioDynamics’ first-quarter fiscal 2027 results. Revenue rises 6.9% from a year earlier to $80.9 million. The adjusted loss narrows to 4 cents per share from 10 cents a year earlier. An adjusted loss excludes certain costs, giving investors another way to track the company’s operating performance and financial health.

Med Tech sales grow 13.2% to $39.9 million, with AlphaVac sales up 37.4%. Gross margin reaches 59.4%, an increase of 410 basis points, or 4.1 percentage points. Gross margin shows how much sales revenue remains after direct production costs. The operating loss narrows to $7.3 million, as highlighted by Zacks.

The stronger Q1 fiscal results do not prevent a sharp share-price drop. Shares fall more than 21% on Thursday despite beating analysts’ earnings expectations, as highlighted by Benzinga. About 1.94 million shares change hands, nearly 3.8 times the 100-day average. AngioDynamics also names Eric Honroth president and CEO, effective Nov. 2, succeeding Jim Clemmer.

About the Author
Andrew Wynn

Market news and analyst rating coverage

Andrew Wynn writes market news and analyst-rating coverage for the FMP blog, tracking price-target revisions, broker upgrades and downgrades, and earnings developments across U.S. equities. His posts distill fast-moving market events into clear, factual summaries grounded in financial data.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account